Voltage-gated potassium channels as therapeutic targets

Nature Reviews Drug Discovery

Volumn 8, Issue 12, 2009, Pages 982-1001

  Wulff, Heike ^a   Castle, Neil A ^b   Pardo, Luis A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Icagen Inc   (United States)

^c MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; 4 AMINOPYRIDINE; AMIODARONE; AZIMILIDE; CLOFAZIMINE; POTASSIUM CHANNEL KCNQ4; POTASSIUM CHANNEL KCNQ5; POTASSIUM CHANNEL KV1.1; POTASSIUM CHANNEL KV1.2; POTASSIUM CHANNEL KV1.3; POTASSIUM CHANNEL KV1.4; POTASSIUM CHANNEL KV1.5; POTASSIUM CHANNEL KV1.6; POTASSIUM CHANNEL KV1.7; POTASSIUM CHANNEL KV1.8; POTASSIUM CHANNEL KV2.1; POTASSIUM CHANNEL KV2.2; POTASSIUM CHANNEL KV3.1; POTASSIUM CHANNEL KV3.2; POTASSIUM CHANNEL KV3.3; POTASSIUM CHANNEL KV3.4; POTASSIUM CHANNEL KV4.1; POTASSIUM CHANNEL KV4.2; POTASSIUM CHANNEL KV4.3; POTASSIUM CHANNEL KV7.1; POTASSIUM CHANNEL KV7.2; POTASSIUM CHANNEL KV7.3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERNAKALANT; VOLTAGE GATED POTASSIUM CHANNEL; ANTIBODY; PEPTIDE; VENOM;

ACTION POTENTIAL; AUTOIMMUNE DISEASE; CALCIUM SIGNALING; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CELL VOLUME; CLINICAL TRIAL; DISCOID LUPUS ERYTHEMATOSUS; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN GENOME; LEPROSY; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUSTULAR PSORIASIS; REPOLARIZATION; REVIEW; SPINAL CORD INJURY; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; PEPTIDES; POTASSIUM CHANNELS, VOLTAGE-GATED; SIGNAL TRANSDUCTION; VENOMS;

EID: 73449119314     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2983     Document Type: Review

References (260)

1. Harmar, A. J. et al. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Res. 37, D680-D685 (2009).
2. Papazian, D. M., Schwarz, T. L., Tempel, B. L., Jan, Y. N. & Jan, L. Y. Cloning of genomic and complementary DNA from Shaker, a putative potassium channel gene from Drosophila. Science 237, 749-753 (1987).
3. + channel. Science 309, 897-903 (2005).
4. Long, S. B., Campbell, E. B. & Mackinnon, R. Voltage sensor of Kv1.2: structural basis of electromechanical coupling. Science 309, 903-908 (2005).
5. Swartz, K. J. Towards a structural view of gating in potassium channels. Nature Rev. Neurosci. 5, 905-916 (2004).
6. Bezanilla, F. Ion channels: from conductance to structure. Neuron 60, 456-468 (2008).
7. Bezanilla, F. How membrane proteins sense voltage. Nature Rev. Mol. Cell Biol. 9, 323-332 (2008).
8. Gutman, G. A. et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol. Rev. 57, 473-508 (2005).
9. + channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem. Rev. 108, 1744-1773 (2008).
10. Chandy, K. G. et al. Potassium channels as targets for specific immunomodulation. Trends Pharmacol. Sci. 25, 280-289 (2004).
11. Feske, S. et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 441, 179-185 (2006).
12. +channels. EMBO J. 18, 5540-5547 (1999).
13. Yang, S., Zhang, J. J. & Huang, X. Y. Orai1 and STIM1 are critical for breast tumour cell migration and metastasis. Cancer Cell 15, 124-134 (2009).
14. Monet, M. et al. Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim. Biophys. Acta 1793, 528-539 (2009).
15. + channels. Proc. Natl Acad. Sci. USA 103, 2886-2891 (2006).
16. Feinshreiber, L., Singer-Lahat, D., Ashery, U. & Lotan, I. Voltage-gated potassium channel as a facilitator of exocytosis. Ann. New York Acad. Sci. 1152, 87-92 (2009).
17. Kaczmarek, L. K. Non-conducting functions of voltage-gated ion channels. Nature Rev. Neurosci. 7, 761-771 (2006).
18. Downie, B. R. et al. Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumours. J. Biol. Chem. 283, 36234-36240 (2008).
19. Hebert, S. C., Desir, G., Giebisch, G. & Wang, W. Molecular diversity and regulation of renal potassium channels. Physiol. Rev. 85, 319-371 (2005).
20. Zhou, B. Y., Ma, W. & Huang, X. Y. Specific antibodies to the external vestibule of voltage-gated potassium channels block current. J. Gen. Physiol. 111, 555-563 (1998).
21. Bruhova, I. & Zhorov, B. S. Monte Carlo-energy minimization of correolide in the Kv1.3 channel: possible role of potassium ion in ligand-receptor interactions. BMC Struct. Biol. 7, 5 (2007).
22. + channel block. J. Biol. Chem. 277, 23587-23595 (2002).
23. + channel and its structural implications. Nature 403, 321-325 (2000).
24. Sanguinetti, M. C. & Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. Nature 440, 463-469 (2006).
25. Wuttke, T. V., Seebohm, G., Bail, S., Maljevic, S. & Lerche, H. The new anticonvulsant retigabine favours voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol. Pharmacol. 67, 1009-1017 (2005).
26. Zhang, Z. H., Rhodes, K. J., Childers, W. E., Argentieri, T. M. & Wang, Q. Disinactivation of N-type inactivation of voltage-gated K channels by an erbstatin analogue. J. Biol. Chem. 279, 29226-29230 (2004).
27. Lu, Q. et al. Disruption of Kv1.1 N-type inactivation by novel small molecule inhibitors (disinactivators). Bioorg. Med. Chem. 16, 3067-3075 (2008).
28. Dabrowski, M. A. et al. Ion channel screening technology. CNS Neurol. Disord. Drug Targets 7, 122-128 (2008).
29. Coleman, S. K., Newcombe, J., Pryke, J. & Dolly, J. O. Subunit composition of Kv1 channels in human CNS. J. Neurochem. 73, 849-858 (1999).
30. + channel blocker. Neurosci. Lett. 139, 34-40 (1992).
31. V1.1 potassium channel causes epilepsy in mice. Neuron 20, 809-819 (1998).
32. Brew, H. M. et al. Seizures and reduced life span in mice lacking the potassium channel subunit Kv1.2, but hypoexcitability and enlarged Kv1 currents in auditory neurons. J. Neurophysiol. 98, 1501-1525 (2007).
33. Zuberi, S. M. et al. A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy. Brain 122, 817-825 (1999).
34. Schulte, U. et al. The epilepsy-linked Lgi1 protein assembles into presynaptic Kv1 channels and inhibits inactivation by Kvβ1. Neuron 49, 697-706 (2006).
35. Hogg, D. S., Ryan, R. & Kozlowski, R. Z. Ion channels and protein-protein interactions: novel approaches to mining validated targets. Drug Discov. Int. 2007, 20-22 (2007).
36. Lawton, G. Potassium channel modulators and uses thereof. WO 2008149163 (2008).
37. Nashmi, R. & Fehlings, M. G. Mechanisms of axonal dysfunction after spinal cord injury: with an emphasis on the role of voltage-gated potassium channels. Brain Res. 38, 165-191 (2001).
38. Hayes, K. C. The use of 4-aminopyridine (fampridine) in demyelinating disorders. CNS Drug Rev. 10, 295-316 (2004).
39. Karimi-Abdolrezaee, S., Eftekharpour, E. & Fehlings, M. G. Temporal and spatial patterns of Kv1.1 and Kv1.2 protein and gene expression in spinal cord white matter after acute and chronic spinal cord injury in rats: implications for axonal pathophysiology after neurotrauma. Eur. J. Neurosci. 19, 577-589 (2004).
40. Korenke, A. R., Rivey, M. P. & Allington, D. R. Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Ann. Pharmacother. 42, 1458-1465 (2008).
41. Goodman, A. D. et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373, 732-738 (2009).
42. Browne, D. L. et al. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nature Genet. 8, 136-140 (1994).
43. Glaudemans, B. et al. A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia. J. Clin. Invest. 19, 936-942 (2009).
44. + channels in human T lymphocytes: a role in mitogenesis? Nature 307, 465-468 (1984).
45. Matteson, D. R. & Deutsch, C. K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature 307, 468-471 (1984).
46. Lin, C. S. et al. Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J. Exp. Med. 177, 637-645 (1993).
47. Koo, G. C. et al. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J. Immunol. 158, 5120-5128 (1997).
48. 2+ store to the plasma membrane. Nature 437, 902-905 (2005).
49. 2+ entry. Science 312, 1220-1223 (2006).
50. Feske, S. Calcium signalling in lymphocyte activation and disease. Nature Rev. Immunol. 7, 690-702 (2007).
51. Wulff, H., Beeton, C. & Chandy, K. G. Potassium channels as therapeutic targets for autoimmune disorders. Curr. Opin. Drug Discov. Devel. 6, 640-647 (2003).
52. Liu, Q.-H. et al. Modulation of Kv channel expression and function by TCR and co-stimulatory signals during peripheral CD4+ lymphocyte differentiation. J. Exp. Med. 196, 897-909 (2002).
53. Beeton, C. & Chandy, K. G. Potassium channels, memory T cells and multiple sclerosis. Neuroscientist 11, 550-562 (2005).
54. + channel in effector memory T cells as new target for MS. J. Clin. Invest. 111, 1703-1713 (2003).
55. Beeton, C. et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl Acad. Sci. USA 103, 17414-17419 (2006).
56. Matheu, M. P. et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity 29, 602-614 (2008).
57. Wulff, H. & Pennington, M. Targeting effector memory T-cells with Kv1.3 blockers. Curr. Opin. Drug Discov. Devel. 10, 438-445 (2007).
58. - co-stimulation-independent T cells in multiple sclerosis. J. Clin. Invest. 108, 1185-1194 (2001).
59. Viglietta, V., Kent, S. C., Orban, T. & Hafler, D. A. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J. Clin. Invest. 109, 895-903 (2002).
60. Kivisakk, P. et al. Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann. Neurol. 55, 627-638 (2004).
61. Rus, H. et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc. Natl Acad. Sci. USA 102, 11094-11099 (2005).
62. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl Acad. Sci. USA 98, 13942-13947 (2001).
63. Beeton, C. et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol. Pharmacol. 67, 1369-1381 (2005).
64. Sullivan, J. K. et al. Fusion proteins of toxin peptides with linkers and IgG and their use as therapeutic agents. WO 2006116156 (2006).
65. Schmitz, A. et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol. Pharmacol. 68, 1254-1270 (2005).
66. Baell, J. B. et al. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. J. Med. Chem. 47, 2326-2336 (2004).
67. Harvey, A. J., Baell, J. B., Toovey, N., Homerick, D. & Wulff, H. A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4-or 7-position of khellinone. J. Med. Chem. 49, 1433-1441 (2006).
68. Azam, P., Sankaranarayanan, A., Homerick, D., Griffey, S. & Wulff, H. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J. Invest. Dermatol. 127, 1419-1429 (2007).
69. Ren, Y. R. et al. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS ONE 3, e4009 (2008).
70. Xu, J. et al. The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight. Hum. Mol. Gen. 12, 551-559 (2003).
71. Xu, J. et al. The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity. Proc. Natl Acad. Sci. USA 101, 3112-3117 (2004).
72. Tucker, K., Overton, J. M. & Fadool, D. A. Kv1.3 gene-targeted deletion alters longevity and reduces adiposity by increasing locomotion and metabolism in melanocortin-4 receptor-null mice. Int. J. Obes. 32, 1222-1232 (2008).
73. Lucero, M. T. & Pappone, P. A. Voltage-gated potassium channels in brown fat cells. J. Gen. Physiol. 93, 451-472 (1989).
74. Pappone, P. A. & Ortiz-Miranda, S. I. Blockers of voltage-gated K channels inhibit proliferation of cultured brown fat cells. Am. J. Physiol. 264, C1014-C1019 (1993).
75. Ramirez-Ponce, M. P., Mateos, J. C., Carrion, N. & Bellido, J. A. Voltage-dependent potassium channels in white adipocytes. Biochem. Biophys. Res. Commun. 223, 250-256 (1996).
76. Ramirez-Ponce, M. P., Mateos, J. C. & Bellido, J. A. Human adipose cells have voltage-dependent potassium currents. J. Membr. Biol. 196, 129-134 (2003).
77. + channel cDNAs from human ventricle. FASEB J. 5, 331-337 (1991).
78. + channel from vascular and visceral smooth muscles. Am. J. Physiol. 267, C1231-C1238 (1994).
79. + channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J. Clin. Invest. 101, 2319-2330 (1998).
80. + current similar to Kv1.5 cloned channel currents. Cir. Res. 73, 1061-1076 (1993).
81. Fedida, D. et al. Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Cir. Res. 73, 210-216 (1993). (Pubitemid 23173072)
82. Wettwer, E. et al. Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 110, 2299-2306 (2004).
83. Brendel, J. & Peukert, S. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Curr. Med. Chem. 1, 273-287 (2003).
84. Kur/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin. Investig. Drugs 18, 399-416 (2009).
85. Ford, J. W. & Milnes, J. T. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value. J. Cardiovas. Pharmacol. 52, 105-120 (2008).
86. Gross, M. F. et al. Aryl sulphonamido indane inhibitors of the Kv1.5 ion channel. Bioorg. Med. Chem. Lett. 17, 2849-2853 (2007).
87. Lloyd, J. et al. Benzopyran sulphonamides as KV1.5 potassium channel blockers. Bioorg. Med. Chem. Lett. 17, 3271-3275 (2007).
88. Kr blockers dofetilide, azimilide, d, l-sotalol and ibutilide. Naunyn-Schmiedeberg. Arch. Pharmacol. 366, 482-487 (2002).
89. +-channel- blocker AVE0118 in anesthetized pigs. Cardiovasc. Res. 60, 298-306 (2003).
90. Gogelein, H. et al. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn-Schmiedeberg. Arch. Pharmacol. 370, 183-192 (2004).
91. Trotter, B. W. et al. Design and synthesis of novel isoquinoline-3- nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation. J. Med. Chem. 49, 6954-6957 (2006).
92. + channels and ultrarapidly activating delayed rectifier potassium current. J. Pharmacol. Exp. Ther. 317, 1054-1063 (2006).
93. Regan, C. P. et al. Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)m ethyl]-6-methoxy-2-methyl-4- phenylisoquinolin-1(2H)-one and 2-phenyl-1, 1-dipyridin-3-yl-2-pyrrolidin-1-yl- ethanol in dogs with underlying heart failure. J. Pharmacol. Exp. Ther. 324, 322-330 (2008).
94. Fluxe, A. et al. Discovery and synthesis of tetrahydroindolone-derived carbamates as Kv1.5 blockers. Bioorg. Med. Chem. Lett. 16, 5855-5858 (2006). (Pubitemid 44486728)
95. Wu, S. et al. Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers. Bioorg. Med. Chem. Lett. 16, 6213-6218 (2006).
96. Eldstrom, J. et al. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. Mol. Pharmacol. 72, 1522-1534 (2007).
97. Fedida, D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert. Opin. Investig. Drugs 16, 519-532 (2007).
98. Naccarelli, G. V. et al. Vernakalant: pharmacology electrophysiology, safety and efficacy. Drugs Today 44, 325-329 (2008).
99. Janusz, J. M. et al. Kv1.5 potassium channel inhibitors. WO 2007149873 (2009).
100. Wirth, K. J. et al. In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231. J. Cardiovasc. Pharmacol. 49, 197-206 (2007).
101. Ehrlich, J. R. et al. Characterization of human cardiac Kv1.5 inhibition by the novel atrial-selective antiarrhythmic compound AVE1231. J. Cardiovasc. Pharmacol. 51, 380-387 (2008).
102. Rivard, L. et al. Electrophysiological and atrial antiarrhythmic effects of a novel IKur/Kv1.5 blocker in dogs. Heart Rhythm 2, S180 (2005).
103. Shiroshita-Takeshita, A., Maltais, C., Ford, J., Madge, D. & Nattel, S. Electrophysiological and atrial antiarrhythmic effects of a novel IKUR/Kv1.5 blocker in dogs with atrial tachycardia remodeling. Heart Rhythm 3, S183-S183 (2005).
104. + channels. J. Biol. Chem. 272, 24371-24379 (1997).
105. Ottschytsch, N., Raes, A., Van Hoorick, D. & Snyders, D. J. Obligatory heterotetramerization of three previously uncharacterized Kv channel alpha-subunits identified in the human genome. Proc. Natl Acad. Sci. USA 99, 7986-7991 (2002).
106. Jacobson, D. A. et al. Kv2.1 ablation alters glucose-induced islet electrical activity, enhancing insulin secretion. Cell Metabol. 6, 229-235 (2007).
107. Dai, X. Q., Kolic, J., Marchi, P., Sipione, S. & Macdonald, P. E. SUMOylation regulates Kv2.1 and modulates pancreatic β-cell excitability. J. Cell Sci. 122, 775-779 (2009).
108. + channels: tuning beta-cell excitability with syntaxin-1A and other exocytotic proteins. Endocr. Rev. 28, 653-663 (2007).
109. Zhuang, G. Q. et al. SNAP-25(1-180) enhances insulin secretion by blocking Kv2.1 channels in rat pancreatic islet beta-cells. Biochem. Biophys. Res. Commun. 379, 812-816 (2009).
110. Veh, R. W. et al. Immunohistochemical localization of five members of the Kv1 channel subunits: contrasting subcellular locations and neuron-specific co-localizations in rat brain. Eur. J. Neurosci. 7, 2189-2205 (1995).
111. Abbott, G. W. et al. MiRP2 forms potassium channels in skeletal muscle with Kv3.4 and is associated with periodic paralysis. Cell 104, 217-231 (2001).
112. Angulo, E. et al. Upregulation of the Kv3.4 potassium channel subunit in early stages of Alzheimer's disease. J. Neurochem. 91, 547-557 (2004).
113. Pannaccione, A. et al. Upregulation and increased activity of KV3.4 channels and their accessory subunit MinK-related peptide 2 induced by amyloid peptide are involved in apoptotic neuronal death. Mol. Pharmacol. 72, 665-673 (2007).
114. Yu, H. B., Li, Z. B., Zhang, H. X. & Wang, X. L. Role of potassium channels in Aβ (1-40)-activated apoptotic pathway in cultured cortical neurons. J. Neurosci. Res. 84, 1475-1484 (2006).
115. + channel blocker 4-aminopyridine protects against kainate-induced neuronal cell death through activation of NMDA receptors in murine hippocampus. Neuropharmacology 48, 810-821 (2005).
116. Birnbaum, S. G. et al. Structure and function of Kv4-family transient potassium channels. Physiol. Rev. 84, 803-833 (2004).
117. + channel in ventricular muscle. A molecular correlate for the transient outward current. Circ. Res. 79, 659-668 (1996).
118. Hohnloser, S. H., Dorian, P., Straub, M., Beckmann, K. & Kowey, P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J. Am. Col. Cardiol. 44, 99-104 (2004).
119. Hu, H. J. et al. The Kv4.2 potassium channel subunit is required for pain plasticity. Neuron 50, 89-100 (2006).
120. Jespersen, T., Grunnet, M. & Olesen, S. P. The KCNQ1 potassium channel: from gene to physiological function. Physiology 20, 408-416 (2005).
121. Brown, D. A. & Passmore, G. M. Neural KCNQ (Kv7) channels. Br. J. Pharmacol. 156, 1185-1195 (2009).
122. Ks potassium channel. Nature 384, 80-83 (1996).
123. Peroz, D. et al. Kv7.1 (KCNQ1) properties and channelopathies. J. Physiol. (Lond). 586, 1785-1789 (2008).
124. Duggal, P. et al. Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of Long-QT syndrome. Circulation 97, 142-146 (1998).
125. Bellocq, C. et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 109, 2394-2397 (2004).
126. Chen, Y. H. et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 299, 251-254 (2003).
127. Lai, L., Su, M., Tseng, Y. & Lien, W. Sensitivity of the slow component of the delayed rectifier potassium current (IKs) to potassium channel blockers: implications for clinical reverse use-dependent effects. J. Biomed. Sci. 6, 251-259 (1999).
128. Nattel, S., Liu, L. & St-Georges, D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc. Res. 37, 627-635 (1998).
129. Gerlach, U. Blockers of the slowly delayed rectifier potassium IKs channel: potential antiarrhythmic agents. Curr. Med. Chem. 1, 243-252 (2003).
130. Pritchett, E. L. & Marcello, S. R. Azimilide for atrial fibrillation: clinical trial results and implications. Card. Electrophysiol. Rev. 7, 215-219 (2003).
131. Pritchett, E. L. et al. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. Am. Heart J. 151, 1043-1049 (2006).
132. Viswanathan, M. N. & Page, R. L. Pharmacological therapy for atrial fibrillation: current options and new agents. Expert Opin. Investig. Drugs 18, 417-431 (2009).
133. Gogelein, H., Bruggemann, A., Gerlach, U., Brendel, J. & Busch, A. E. Inhibition of IKs channels by HMR 1556. Naunyn-Schmiedeberg. Arch. Pharmacol. 362, 480-488 (2000).
134. Thomas, G. P., Gerlach, U. & Antzelevitch, C. HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. J. Cardiovasc. Pharmacol. 41, 140-147 (2003).
135. So, P. P., Hu, X. D., Backx, P. H., Puglisi, J. L. & Dorian, P. Blockade of IKs by HMR 1556 increases the reverse rate-dependence of refractoriness prolongation by dofetilide in isolated rabbit ventricles. Br. J. Pharmacol. 148, 255-263 (2006).
136. Ks-blocking agent HMR 1556 restores sinus rhythm and prevents heart failure in pigs with persistent atrial fibrillation. Basic Res. Cardiol. 100, 270-278 (2005).
137. Nakashima, H., Gerlach, U., Schmidt, D. & Nattel, S. In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions. Cardiovasc. Res. 61, 705-714 (2004).
138. Ks, in canine models of malignant ischemic ventricular arrhythmia. Circulation 100, 1917-1922 (1999).
139. Busch, A. E. et al. Positive regulation by chloride channel blockers of IsK channels expressed in Xenopus oocytes. Mol. Pharmacol. 46, 750-753 (1994).
140. + current in canine ventricular cardiomyocytes. Naunyn-Schmiedeberg. Arch. Pharmacol. 373, 85-89 (2006).
141. + currents. Mol. Pharmacol. 54, 220-230 (1998).
142. Schroeder, B. C. et al. A constitutively open potassium channel formed by KCNQ1 and KCNE3. Nature 403, 196-199 (2000).
143. + channel KvLQT1 and epithelial function. Pflugers Arch. 440, 202-206 (2000).
144. - secretion in human airway epithelia. Am. J. Respir. Cell. Mol. Biol. 23, 283-289 (2000).
145. Vallon, V. et al. KCNQ1-dependent transport in renal and gastrointestinal epithelia. Proc. Natl Acad. Sci. USA 102, 17864-17869 (2005).
146. Yasuda, K. et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nature Genet. 40, 1092-1097 (2008).
147. Boini, K. M. et al. Enhanced insulin sensitivity of gene targeted mice lacking functional KCNQ1. Am. J. Physiol. 296, R1695-R1701 (2009).
148. Marrion, N. V. Control of M-current. Ann. Rev. Physiol. 59, 483-504 (1997).
149. Biervert, C. et al. A potassium channel mutation in neonatal human epilepsy. Science 279, 403-406 (1998).
150. Wang, H. S. et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 282, 1890-1893 (1998).
151. Schroeder, B. C., Hechenberger, M., Weinreich, F., Kubisch, C. & Jentsch, T. J. KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J. Biol. Chem. 275, 24089-24095 (2000).
152. Kubisch, C. et al. KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell 96, 437-446 (1999).
153. Van Eyken, E. et al. KCNQ4: a gene for age-related hearing impairment? Hum. Mutat. 27, 1007-1016 (2006).
154. Fontana, D. J., Inouye, G. T. & Johnson, R. M. Linopirdine (DuP 996) improves performance in several tests of learning and memory by modulation of cholinergic neurotransmission. Pharmacol. Biochem. Behav. 49, 1075-1082 (1994).
155. Borjesson, A., Karlsson, T., Adolfsson, R., Ronnlund, M. & Nilsson, L. Linopirdine (DUP 996): cholinergic treatment of older adults using successive and non-successive tests. Neuropsychobiology 40, 78-85 (1999).
156. Zaczek, R. et al. Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4- pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. J. Pharmacol. Exp. Ther. 285, 724-730 (1998).
157. Wickenden, A. D., Yu, W., Zou, A., Jegla, T. & Wagoner, P. K. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol. Pharmacol. 58, 591-600 (2000).
158. Rundfeldt, C. & Netzer, R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci. Lett. 282, 73-76 (2000).
159. Main, M. J. et al. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol. Pharmacol. 58, 253-262 (2000).
160. Blackburn-Munro, G., Dalby-Brown, W., Mirza, N. R., Mikkelsen, J. D. & Blackburn-Munro, R. E. Retigabine: chemical synthesis to clinical application. CNS Drug Rev. 11, 1-20 (2005).
161. Plosker, G. L. & Scott, L. J. Retigabine: in partial seizures. CNS Drugs 20, 601-610 (2006).
162. Porter, R. J., Nohria, V. & Rundfeldt, C. Retigabine. Neurotherapeutics 4, 149-154 (2007).
163. French, J. & Mansbach, H. 1200 mg/day retigabine as adjunctive therapy in adults with refractory partial-onset seizures. American Epilepsy Society Meeting (Seattle, Washington, 2008).
164. Brodie, M. & Mansbach, H. Retigabine 600 or 900 mg/day as adjunctive therapy in adults with partial-onset seizures. American Epilepsy Society Meeting (Seattle, Washington, 2008).
165. Wickenden, A. D. et al. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator. Mol. Pharmacol. 73, 977-986 (2008).
166. Roeloffs, R. et al. In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3- yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models. J. Pharmacol. Exp. Ther. 326, 818-828 (2008).
167. Rigdon, G. C. Results of phase 1 program for ICA-105665, drug candidate for the treatment of epilepsy and neuropathic pain. Antiepileptic Drug Trials X Conference (Coral Gables, Florida, 2009).
168. Passmore, G. M. et al. KCNQ/M currents in sensory neurons: significance for pain therapy. J. Neurosci. 23, 7227-7236 (2003).
169. Gerlach, A., Stoehr, S. J. & Rigdon, G. C. Sub-type selective activation of KCNQ2/3 channels modulates the excitability of nociceptive dorsal root ganglion neurons. Society of Neuroscience Meeting (San Diego, California, 2007).
170. Munro, G. & Dalby-Brown, W. Kv7 (KCNQ) channel modulators and neuropathic pain. J. Med. Chem. 50, 2576-2582 (2007).
171. Wickenden, A. D. & McNaughton-Smith, G. Kv7 channels as targets for the treatment of pain. Curr. Pharm. Des. 15, 1773-1798 (2009).
172. Ilyin, V., Carlin, K. P., Hodges, D. D., Robeldo, S. & Woodward, R. M. Flupirtine: A positive modulator of heteromeric KCNQ2/Q3 channels. Society of Neuroscience Meeting (Orlando, Florida, 2002).
173. Blackburn-Munro, G. & Jensen, B. S. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur. J. Pharmacol. 460, 109-116 (2003).
174. Hirano, K. et al. Kv7.2-7.5 voltage-gated potassium channel (KCNQ2-5) opener, retigabine, reduces capsaicin-induced visceral pain in mice. Neurosci. Lett. 413, 159-162 (2007).
175. Leventhal, L. et al. Activity of a KCNQ2/3 opener in rat models of inflammatory pain. Society of Neuroscience Meeting (San Diego, California, 2007).
176. Mark, L. et al. Activity of a KCNQ2/3 opener in rat models of neuropathic pain. Society of Neuroscience Meeting (San Diego, California, 2007).
177. Wickenden, A. D., Roeloffs, R., McNaughton-Smith, G. & Rigdon, G. C. KCNQ potassium channels: drug targets for the treatment of epilepsy and pain. Expert Opin. Ther. Pat. 14, 1-13 (2004).
178. Wua, Y. J. & Dworetzky, S. I. Recent developments on KCNQ potassium channel openers. Curr. Med. Chem. 12, 453-460 (2005).
179. Dworetzky, S. I., Gribkoff, V. K., Kinney, G. G. & Hewawasam, P. 3-Fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease. US 6855829 (2005).
180. Peretz, A. et al. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol. Pharmacol. 67, 1053-1066 (2005).
181. Peretz, A. et al. A tale of switched functions: from cyclooxygenase inhibition to M-channel modulation in new diphenylamine derivatives. PLoS ONE 2, e1332 (2007).
182. Hansen, H. H. et al. Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS. J. Physiol. (Lond). 586, 1823-1832 (2008).
183. Redrobe, J. P. & Nielsen, A. N. Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania. Behav. Brain Res. 198, 481-485 (2009).
184. Sotty, F. et al. Antipsychotic-like effect of retigabine [N-(2-amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission. J. Pharmacol. Exp. Ther. 328, 951-962 (2009).
185. Husum Bak-Jensen, H. et al. Use of KCNQ-openers for treating or reducing the symptoms of schizophrenia. WO 2007090409 (2007).
186. Bak-Jensen, H. H. & Hertel, K. P. Use of KCNQ potassium channel openers for reducing symptoms or treating disorders or conditions wherein the dopaminergic system is disrupted. WO 2009015667 (2009).
187. Argentieri, T. M. & Sheldon, J. H. Methods of selecting compounds for modulation of bladder function. US 7160684 (2007).
188. Haemmerlein, B. et al. Overexpression of Eag1 potassium channels in clinical tumours. Mol. Can. 5, 41 (2006).
189. Occhiodoro, T. et al. Cloning of a human ether-a-go-go potassium channel expressed in myoblasts at the onset of fusion. FEBS Lett. 434, 177-182 (1998).
190. Martin, S. et al. Eag1 potassium channel immunohistochemistry in the CNS of adult rat and selected regions of human brain. Neurosci. 155, 833-844 (2008).
191. + current, ih-eag, contributes to the hyperpolarization of human fusion-competent myoblasts. J. Physiol. (Lond.) 512, 317-323 (1998).
192. Ousingsawat, J. et al. Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. Clin. Cancer Res. 13, 824-831 (2007). (Pubitemid 46340355)
193. Ding, X. W., Yan, J. J., An, P., Lu, P. & Luo, H. S. Aberrant expression of ether a go-go potassium channel in colorectal cancer patients and cell lines. World J. Gastroenterol. 13, 1257-1261 (2007).
194. Ding, X. W., Luo, H. S., Jin, X., Yan, J. J. & Ai, Y. W. Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines. Med. Oncol. 24, 345-350 (2007).
195. Mello de Queiroz, F., Suarez-Kurtz, G., Stuhmer, W. & Pardo, L. A. Ether a go-go potassium channel expression in soft tissue sarcoma patients. Mol. Cancer 5, 42 (2006).
196. Diaz, L. et al. Estrogens and human papilloma virus oncogenes regulate human ether-a-go-go-1 potassium channel expression. Cancer Res. 69, 3300-3307 (2009).
197. Weber, C. et al. Silencing the activity and proliferative properties of the human Eag1 potassium channel by RNAi. J. Biol. Chem. 281, 13033-13037 (2006).
198. + currents of cells expressing human ether a go-go channels. Life Sci. 81, 255-265 (2007).
199. Gavrilova-Ruch, O. et al. Effects of imipramine on ion channels and proliferation of IGR1 melanoma cells. J. Membr. Biol. 188, 137-149 (2002).
200. + channel. Recept. Channels 7, 345-356 (2001).
201. + channel function in the human mammary carcinoma cell line MCF-7. Oncol. Rep. 19, 1511-1516 (2008).
202. Hancox, J. C., McPate, M. J., El Harchi, A. & Zhang, Y. H. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol. Ther. 11 9, 118-132 (2008).
203. Gomez-Varela, D. et al. Different relevance of inactivation and F468 residue in the mechanisms of hEag1 channel blockage by astemizole, imipramine and dofetilide. FEBS Lett. 580, 5059-5066 (2006).
204. Gomez-Varela, D. et al. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumour activity. Cancer Res. 67, 7343-7349 (2007).
205. Grunnet, M., Hansen, R. S. & Olesen, S. P. hERG1 channel activators: a new anti-arrhythmic principle. Prog. Biophys. Mol. Biol. 98, 347-362 (2008).
206. Sanguinetti, M. C., Jiang, C., Curran, M. E. & Keating, M. T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81, 299-307 (1995).
207. Kamath, G. S. & Mittal, S. The role of antiarrhythmic drug therapy for the prevention of sudden cardiac death. Prog. Cardiovasc. Dis. 50, 439-448 (2008).
208. Hansen, R. S. et al. Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl- phenyl)-urea (NS1643). Mol Pharmacol. 69, 266-277 (2006).
209. Hansen, R. S. et al. Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5- yl)-phenyl)-N'-(3'-trifluoromethylphenyl)urea]. Mol. Pharmacol. 70, 1319-1329 (2006).
210. + channel. Mol. Pharmacol. 67, 827-836 (2005).
211. Zhou, J. et al. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol. Pharmacol. 68, 876-884 (2005).
212. Su, Z. et al. Electrophysiologic characterization of a novel hERG channel activator. Biochem. Pharmacol. 77, 1383-1390 (2009).
213. Zeng, H. et al. Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator. J. Pharmacol. Exp. Ther. 319, 957-962 (2006).
214. Gussak, I. & Antzelevitch, C. Early repolarization syndrome: clinical characteristics and possible cellular and ionic mechanisms. J. Electrocardiol. 33, 299-309 (2000).
215. Anderson, C. L. et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 11 3, 365-373 (2006).
216. Zhou, Z., Gong, Q. & January, C. T. Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. J. Biol. Chem. 274, 31123-31126 (1999).
217. Dennis, A., Wang, L., Wan, X. & Ficker, E. hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem. Soc. Trans. 35, 1060-1063 (2007).
218. Huffaker, S. J. et al. A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nature Med. 15, 509-518 (2009).
219. Arcangeli, A. Expression and role of hERG channels in cancer cells. Novartis Found. Symp. 266, 225-232 (2005).
220. + current highly conserved in tumours of different histogenesis-a selective advantage for cancer cells? Cancer Res. 58, 815-822 (1998).
221. Cherubini, A. et al. HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. Br. J. Cancer 83, 1722-1729 (2000).
222. Pillozzi, S. et al. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic haemopoietic progenitors. Leukemia 16, 1791-1798 (2002).
223. Lastraioli, E. et al. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumour cells. Cancer Res. 64, 606-611 (2004).
224. Masi, A. et al. hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br. J. Cancer 93, 781-792 (2005).
225. Lastraioli, E. et al. hERG1 channels in human esophagus: evidence for their aberrant expression in the malignant progression of Barrett's esophagus. J. Cell. Physiol. 209, 398-404 (2006).
226. + channel form a macromolecular signalling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 11 0, 1238-1250 (2007).
227. Crociani, O. et al. Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumour cells. J. Biol. Chem. 278, 2947-2955 (2003).
228. + channel expression and hERG1 current density in tumour cells. Mol. Cell. Biol. 28, 5043-5060 (2008).
229. Ganapathi, S. B., Kester, M. & Elmslie, K. S. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. Am. J. Physiol. Cell. Physiol. 296, C701-C710 (2009).
230. + channel induces skeletal muscle atrophy by activating the ubiquitin proteasome pathway. FASEB J. 20, 1531-1533 (2006).
231. Watanabe, H. et al. Disruption of the epilepsy KCNQ2 gene results in neural hyperexcitability. J. Neurochem. 75, 28-33 (2000).
232. Peters, H. C., Hu, H., Pongs, O., Storm, J. F. & Isbrandt, D. Conditional transgenic suppression of M channels in mouse brain reveals functions in neuronal excitability, resonance and behaviour. Nature Neurosci. 8, 51-60 (2005).
233. Nerbonne, J. M. Studying cardiac arrhythmias in the mouse-a reasonable model for probing mechanisms? Trends Cardiovasc. Med. 14, 83-93 (2004).
234. Tytgat, J. et al. A unified nomenclature for short-chain peptides isolated from scorpion venoms: alpha-KTx molecular subfamilies. Trends Pharmacol. Sci. 20, 444-447 (1999).
235. MacKinnon, R. & Miller, C. Mutant potassium channels with altered binding of charybdotoxin, a pore-blocking peptide inhibitor. Science 245, 1382-1385 (1989).
236. MacKinnon, R., Heginbotham, L. & Abramson, T. Mapping the receptor site for charybdotoxin, a pore-blocking potassium channel inhibitor. Neuron 5, 767-771 (1990).
237. Chandy, K. G. et al. Potassium channels in T lymphocytes: toxins to therapeutic immuno-suppressants. Toxicon 39, 1269-1276 (2001).
238. + channel through multiple binding sites. Neuron 18, 665-673 (1997).
239. Swartz, K. J. Tarantula toxins interacting with voltage sensors in potassium channels. Toxicon 49, 213-230 (2007).
240. Phillips, L. R. et al. Voltage-sensor activation with a tarantula toxin as cargo. Nature 436, 857-860 (2005).
241. Lee, S. Y. & MacKinnon, R. A membrane-access mechanism of ion channel inhibition by voltage sensor toxins from spider venom. Nature 430, 232-235 (2004).
242. Hamill, O. P., Marty, A., Neher, E., Sakmann, B. & Sigworth, F. J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 391, 85-100 (1981).
243. V1.3 expressed in CHO cells. Biochemistry 36, 3737-3744 (1997).
244. Felix, J. P. et al. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry 38, 4922-4930 (1999).
245. 3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur. J. Pharmacol. 430, 147-148 (2001).
246. Hanson, D. C. et al. UK-78282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation. Br. J. Pharmacol. 126, 1707-1716 (1999).
247. Wang, K. et al. Validation of an atomic absorption rubidium ion efflux assay for KCNQ/M-channels using the Ion Channel Reader 8000. Assay Drug Dev. Technol. 2, 525-534 (2004).
248. Weaver, C. D., Harden, D., Dworetzky, S. I., Robertson, B. & Knox, R. J. A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells. J. Biomol. Screen. 9, 671-677 (2004).
249. Wolff, C., Fuks, B. & Chatelain, P. Comparative study of membrane potential-sensitive fluorescent probes and their use in ion channel screening assays. J. Biomol. Screen. 8, 533-543 (2003).
250. Ghetti, A., Guia, A. & Xu, J. Automated voltage-clamp technique. Methods Mol. Biol. 403, 59-69 (2007).
251. Mathes, C., Friis, S., Finley, M. & Liu, Y. QPatch: the missing link between HTS and ion channel drug discovery. Combin. Chem. High Throughput Screen. 12, 78-95 (2009).
252. V11.1 channels. Combin. Chem. High Throughput Screen. 12, 51-63 (2009).
253. Farre, C. et al. Port-a-patch and patchliner: high fidelity electrophysiology for secondary screening and safety pharmacology. Combin. Chem. High Throughput Screen. 12, 24-37 (2009).
254. Jow, F. et al. Validation of a medium-throughput electro physiological assay for KCNQ2/3 channel enhancers using IonWorks H T. J. Biomol. Screen. 12, 1059-1067 (2007).
255. Dale, T. J., Townsend, C., Hollands, E. C. & Trezise, D. J. Population patch clamp electrophysiology: a breakthrough technology for ion channel screening. Mol. Biosyst. 3, 714-722 (2007).
256. Lu, Q. & An, W. F. Impact of novel screening technologies on ion channel drug discovery. Combin. Chem. High Throughput Screen. 11, 185-194 (2008).
257. Southan, A. & Clark, G. Recent advances in electrophysiology-based screening technology and the impact upon ion channel discovery research. Methods Mol. Biol. 565, 187-208 (2009).
258. Fadool, D. A. et al. Kv1.3 channel gene-targeted deletion produces "Super-Smeller Mice" with altered glomeruli, interacting scaffolding proteins, and biophysics. Neuron 41, 389-404 (2004).
259. Koni, P. A. et al. Compensatory anion currents in Kv1.3 channel-deficient thymocytes. J. Biol. Chem. 278, 39443-39451 (2003).
260. Kopljar, I. et al. A polyether biotoxin binding site on the lipid-exposed face of the pore domain of Kv channels revealed by the marine toxin gambierol. Proc. Natl Acad. Sci. USA 106, 9896-9901 (2009).